
PCUK Career Acceleration Fellow @UniofOxford š¬š§ working to improve radionuclide treatment of prostate cancer with novel drug combinationsš+ā¢ļø.
Oxford
Joined April 2020
- Tweets139
- Following335
- Followers330
- Likes226
Edward O'Neill retweeted
Postdoc/RA jobs in new #radiobiology group @unioxford
ā¢Funder @PCF_Science
ā¢Co-supervision @ProfClaireEd
ā¢Collab with @OxPCaBiol
Project: Identify metabolic signatures in #prostatecancer 𦓠mets w/ PET imaging for tailored š + ā¢ļøcombos
t.ly/3iIrL
Cl 17 Jan
Edward O'Neill retweeted
UK contingent at #PCFRetreat23 Fantastic science, and so great to catch up with friends and colleagues after 4y! Thanks @PCF_Science
Edward O'Neill retweeted
We are thrilled to announced that Dr Edward O'Neill will join our department after securing a prestigious Prostate Cancer UK Career Acceleration Fellowship. Congrats and welcome to NDS, @NuclearMedEd! š
ā”ļø nds.ox.ac.uk/news/edward-oneā¦
@ProstateUKProfs @ProstateUKPress @ProstateUK
Edward O'Neill retweeted
NEW: Oxford's #cancer research has received £11 million investment from @CRUKresearch!
The funding for @OxfordCancer and @OUH_Research will be invested in:
⢠Early detection
⢠Novel therapeutics & diagnostics
⢠Developments in immuno-oncology
⢠Cancer big data
Read moreā¬ļø
Edward O'Neill retweeted
Animation showing the pharmacokinetics of a Lu-PSMA radionuclide therapy for treatment of metastatic prostate cancer. Mapping the rate of uptake and clearance is necessary to estimate the effect in each cycle of treatment which in turn allows more personalised prescription.
Edward O'Neill retweeted
Results released by @ASCO & @Novartis on the Phase 3 VISION trial testing the addition of 177Lu-PSMA-617 to standard of care in mCRPC. Significant improvements in median rPFS (8.7 vs 3.4 months) & median Overall Survival (15.3 vs 11.3 months). #ASCO21 asco.org/about-asco/press-ceā¦
Edward O'Neill retweeted
NEW: Oxford researchers find malaria vaccine is highly effective:
⢠Vaccine efficacy of 77% in African children
⢠Vaccine, trialled in 450 children, shows favourable safety profile and was well-tolerated
More info ā¬ļø
https://nitter.cf/t.co/vOvEuICo2Q
Edward O'Neill retweeted
Super exciting new study showing SARS-CoV-2 recruits a haem metabolite to evade antibodies to the N-terminal domain of Spike ā all started from a curious observation: colour change in purified protein... medrxiv.org/content/10.1101/ā¦
Edward O'Neill retweeted
The ChAdOx1 nCoV-19 vaccine against SARS-CoV-2, which is currently undergoing human clinical trials in the UK, elicits an immune response and reduces the viral load in macaques exposed to SARS-CoV-2, according to a Nature paper. go.nature.com/310Dwoa
Edward O'Neill retweeted
Oxfordās Covid-19 vaccine produces a good immune response, reveals new study.
Teams at @VaccineTrials and @OxfordVacGroup have found there were no safety concerns, and the vaccine stimulated strong immune responses: https://nitter.cf/t.co/krqRzXMh7B
Edward O'Neill retweeted
Our latest "Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following alpha- and beta-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Got the cover too! thno.org/v10p5802.htm #Theranostics
Edward O'Neill retweeted
Thank you to everyone who supported ā150 years of Nature,ā which won two @TheWebbyAwards! Watch the video below.
Edward O'Neill retweeted
A new study published in The Journal of Nuclear Medicine has demonstrated that molecular imaging can identify early response to 177Lu-DOTATATE treatment in neuroendocrine tumor patients. #NeuroendocrineCancer #MedicalResearch #NuclearMedicine #JNM ow.ly/aUq050zFJf0
Edward O'Neill retweeted
Promising new preprint from UK+US researchers showing that a single injection of the Oxford adenovirus that encodes the #COVID19 #SARSCoV2 spike protein (ChAdOx1) serves as an effective vaccine in monkeys, blocking pneumonia & greatly lowering viral load.šbiorxiv.org/content/10.1101/ā¦
Edward O'Neill retweeted
ANNOUNCEMENT: Today SNMMI President Vasken Dilsizian, MD, unveiled the re-imagined SNMMI 2020 Annual MeetingāVirtual Edition! This virtual experience, on July 11-14, will be FREE to SNMMI members, discounted for nonmembers. ow.ly/PwT030qC5h3 #SNMMI20 #NuclearMedicine




















